The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication

Annual Review of Pharmacology and Toxicology

Volumn 54, Issue , 2014, Pages 9-26

  Rask Andersen, Mathias ^a   Masuram, Surendar ^a,b   Schiöth, Helgi B ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA MONITORING CENTRE   (Sweden)

Author keywords

Cancer; Clinical trials; Diabetes; Drug targets; Inflammation; Kinase

Indexed keywords

ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; G PROTEIN COUPLED RECEPTOR; LIGAND; PROTEIN KINASE;

ANTIINFLAMMATORY ACTIVITY; CLINICAL CLASSIFICATION; DATA BASE; DRUG INFORMATION; DRUG MECHANISM; DRUG TARGETING; DRUGGABLE GENOME; FOOD INTAKE; GENETIC PARAMETERS; HUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION;

ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; APPETITE REGULATION; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; EVALUATION STUDIES AS TOPIC; G-PROTEIN-COUPLED RECEPTOR KINASES; GENOME, HUMAN; HUMANS; HYPOGLYCEMIC AGENTS; MOLECULAR TARGETED THERAPY; PROTEOME;

EID: 84891751622     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-011613-135943     Document Type: Review

References (34)

1. Hopkins AL, Groom CR. 2002. The druggable genome. Nat. Rev. Drug Discov. 1:727-30
2. Rask-Andersen M, Almen MS, Schiöth HB. 2011. Trends in the exploitation of novel drug targets. Nat. Rev. Drug Discov. 10:579-90
3. Drews J. 1996. Genomic sciences and the medicine of tomorrow. Nat. Biotechnol. 14:1516-18
4. Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. 1996. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill. 9th ed.
5. Imming P, Sinning C, Meyer A. 2006. Drugs, their targets and the nature and number of drug targets. Nat. Rev. Drug Discov. 5:821-34
6. Overington JP, Al-Lazikani B, Hopkins AL. 2006. How many drug targets are there? Nat. Rev. Drug Discov. 5:993-96
7. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, et al. 2006. Drug Bank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 34:D668-72
8. Knox C, Law V, Jewison T, Liu P, Ly S, et al. 2011. Drug Bank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 39:D1035-41
9. Webb EC. 1992. Enzyme Nomenclature 1992: Recommendations of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology on the Nomenclature and Classification of Enzymes. San Diego: Academic
10. Saier MH Jr, Tran CV, Barabote RD. 2006. TCDB: the Transporter Classification Database for membrane transport protein analyses and information. Nucleic Acids Res. 34:D181-86
11. Saier MH Jr. 2000. A functional-phylogenetic classification system for transmembrane solute transporters. Microbiol. Mol. Biol. Rev. 64:354-411
12. Cohen P. 2002. Protein kinases-the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1:309-15
13. Zhang J, Yang PL, Gray NS. 2009. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9:28-39
14. Lagerstrom MC, Schiöth HB. 2008. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat. Rev. Drug Discov. 7:339-57
15. Berggren R, Moller M, Moss R, Poda P, Smietana K. 2012. Outlook for the next 5 years in drug innovation. Nat. Rev. Drug Discov. 11:435-36
16. McGeary M, Burnstein M. 1999. Sources of cancer research funding in the United States. Rep. Sources Cancer Res. Funding U.S., Natl. Cancer Policy Board, Inst. Med., Wash., D.C.
17. Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, et al. 2007. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356:1517-26
18. Kaufman A, Herold KC. 2009. Anti-CD3 mAbs for treatment of type 1 diabetes. Diabetes Metab. Res. Rev. 25:302-6
19. Aldridge S. 2012. Toll-like receptor blocker slows beta cell death in type 1 diabetes. Nat. Biotechnol. 30:124
20. Citron M. 2010. Alzheimer's disease: strategies for disease modification. Nat. Rev. Drug Discov. 9:387-98
21. Dominguez JM, Fuertes A, Orozco L, del Monte-Millan M, Delgado E, Medina M. 2012. Evidence for irreversible inhibition of glycogen synthase kinase-3βby tideglusib. J. Biol. Chem. 287:893-904
22. Medina M, Garrido JJ, Wandosell FG. 2011. Modulation of GSK-3 as a therapeutic strategy on tau pathologies. Front. Mol. Neurosci. 4:24
23. Dietrich MO, Horvath TL. 2012. Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons. Nat. Rev. Drug Discov. 11:675-91
24. 2C agonist: in vitro and in vivo pharmacological characterization. J. Pharmacol. Exp. Ther. 325:577-87
25. Garcia JM, Friend J, Allen S. 2013. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer 21:129-37
26. Chugh PK, Sharma S. 2012. Recent advances in the pathophysiology and pharmacological treatment of obesity. J. Clin. Pharm. Ther. 37:525-35
27. Lijnen HR, Frederix L, Van Hoef B. 2010. Fumagillin reduces adipose tissue formation in murine models of nutritionally induced obesity. Obesity 18:2241-46
28. Kim YM, An JJ, Jin YJ, Rhee Y, Cha BS, et al. 2007. Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732. J. Mol. Endocrinol. 38:455-65
29. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46:3-26
30. Schmid EF, Smith DA. 2005. Keynote review: Is declining innovation in the pharmaceutical industry a myth? Drug Discov. Today 10:1031-39
31. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, et al. 2010. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9:203-14
32. UniProt Consort. 2012. Reorganizing the protein space at the Universal Protein Resource (UniProt). Nucleic Acids Res. 40:D71-75
33. Almén MS, Nordström KJ, Fredriksson R, Schiöth HB. 2009. Mapping the human membrane proteome: A majority of the human membrane proteins can be classified according to function and evolutionary origin. BMC Biol. 7:50
34. Robinson DR, Wu YM, Lin SF. 2000. The protein tyrosine kinase family of the human genome. Oncogene 19:5548-57